Integrated Filing — IndAS



General information about company

Scrip Code 540797
NSE Symbol SHALBY
MSEI Symbol NOTLISTED
ISIN INE597J01018
Name of company SHALBY LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2025
Date of end of financial year 31-03-2026
Date of board meeting when results were approved 11-02-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 02-02-2026
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter Third quarter
Nature of report standalone or consolidated Consolidated
Whether results are audited or unaudited for the quarter ended Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Unaudited
Segment Reporting Multi segment
Description of single segment
Start date and time of board meeting 11-02-2026   17:58:00
End date and time of board meeting 11-02-2026   18:45:00
Whether cash flow statement is applicable on company
Type of cash flow statement
Declaration of unmodified opinion or statement on impact of audit qualification Not applicable



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-10-2025 01-04-2025
B Date of end of reporting period 31-12-2025 31-12-2025
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Consolidated Consolidated
1 Income
Revenue from operations 27,212.60 85,398.40
Other income 722.80 1,871.10
Total income 27,935.40 87,269.50
2 Expenses
(a) Cost of materials consumed 1,768.80 4,985.10
(b) Purchases of stock-in-trade 3,213.40 9,268.90
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade (1,548.20) (3,472.00)
(d) Employee benefit expense 4,701.70 13,873.30
(e) Finance costs 1,064.10 2,965.70
(f) Depreciation, depletion and amortisation expense 1,761.00 5,150.20
(f) Other Expenses
1 Other Expenses 3,461.00 9,897.70
2 Fees to Doctors and Consultants 6,688.00 20,594.00
3 Other Operative Exp 5,902.60 18,910.90
Total other expenses 16,051.60 49,402.60
Total expenses 27,012.40 82,173.80
3 Total profit before exceptional items and tax 923.00 5,095.70
4 Exceptional items 0.00 0.00
5 Total profit before tax 923.00 5,095.70
6 Tax expense
7 Current tax 717.30 3,979.20
8 Deferred tax 77.90 (506.80)
9 Total tax expenses 795.20 3,472.40
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations 127.80 1,623.30
12 Profit (loss) from discontinued operations before tax 0.00 0.00
13 Tax expense of discontinued operations 0.00 0.00
14 Net profit (loss) from discontinued operation after tax 0.00 0.00
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0.00 0.00
16 Total profit (loss) for period 127.80 1,623.30
17 Other comprehensive income net of taxes (281.20) (1,031.70)
18 Total Comprehensive Income for the period (153.40) 591.60
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent 176.48 1,907.00
Total profit or loss, attributable to non-controlling interests (48.77) (283.77)
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent (281.22) (1,031.81)
Total comprehensive income for the period attributable to owners of parent non-controlling interests 0.02 0.11
21 Details of equity share capital
Paid-up equity share capital 10,751.70 10,751.70
Face value of equity share capital 10 10
27 Details of debt securities
22 Reserves excluding revaluation reserve
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 0.12 1.51
Diluted earnings (loss) per share from continuing operations 0.12 1.51
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 0.12 1.51
Diluted earnings (loss) per share from continuing and discontinued operations 0.12 1.51
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results

Textual Information(1) Notes to the Unaudited Consolidated Financial Results for the Quarter & Nine months ended December 31, 2025 1. The above unaudited consolidated financial results for the quarter and nine months ended December 31, 2025 have been reviewed by the Audit Committee and subsequently approved by the Board of Directors of the company at their respective meetings held on February 11, 2026. The Statutory Auditors of the Company have carried out a Limited Review for said unaudited financial results. 2. These financial results have been prepared in accordance with Indian Accounting Standards (Ind- AS) as prescribed under section 133 of Companies Act 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules 2015 and relevant amendment thereafter. 3. Shalby Limited Employees Welfare Trust has acquired 7,00,000 Equity Shares of Shalby Limited in June 2022 through market purchase pursuant to Employee Stock Option Scheme-2021. Company has granted all 7,00,000 Stock Options to eligible employees, out of which total 4,35,765 Stock Options were lapsed, 2,09,235 Options were vested and 2,08,235 Options exercised by eligible employees as on December 31, 2025 In accordance with the resolution passed by the Nomination and Remuneration Committee, the Company has granted 1,16,000 stock options from the pool of 4,35,765 lapsed options and as of December 31, 2025, a total of 56,000 stock options remain active. 4. The consolidated financial result includes the results of the Company, Shalby Limited and 14 Subsidiary companies (Covering 4 stepdown subsidiaies). The company together with its subsidiaries is herein referred to as the Group viz Shalby (Kenya) Limited, Vrundavan Shalby Hospitals Limited, Yogeshwar Healthcare Limited, Shalby International Limited, Griffin Mediquip LLP, Shalby MedTech Limited (formerly known as Mars Medical Devices Limited), Slaney Healthcare Private Limited, Shalby Hospitals Mumbai Private Limited, PK Healthcare Private Limited, Healers Hospital Private Limited, Shalby Advanced Technologies INC., Shalby Global Technologies Pte Ltd., Ningen Lifecare Private Limited and Shalby Advanced Technologies India Private Limited 5. The Group is not a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P /2018/144 dated November 26, 2018. 6. On November 21, 2025, the Government of India notified provisions of the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020 and the Occupational Safety, Health and Working Conditions Code, 2020, ('Labour Codes') which consolidate twenty nine existing labour laws into a unified framework governing employee benefits during employment and post- employment. Based on management’s assessment, the implementation of the Labour Codes has not resulted in any material financial impact on the Group’s defined benefit obligations as at the reporting date. Accordingly, no adjustment has been recognised in the financial statements for the current quarter and the nine months ended 31st December, 2025. The Group continues to monitor the finalisation of the Central and State Rules, as well as further clarifications from the Government on various aspects of the Labour Codes, and will recognise any impact, if applicable, based on future developments. 7. As per Indian Accounting Standard (Ind AS) 108 - Segment Reporting, segment information has been provided in Consolidated Financial Results. The business segments of the company comprise of Healthcare Activities & Manufacturing of Implant. Disclosure for the same is given in the separate note attached herewith in Annexure I. 8. Previous period figures have been re-grouped, re-cast and re-arranged wherever considered necessary to make it comparable.



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-10-2025 01-04-2025
Date of end of reporting period 31-12-2025 31-12-2025
Whether results are audited or unaudited Unaudited Unaudited
Nature of report standalone or consolidated Consolidated Consolidated
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
1 a) Healthcare Services 24,197.50 76,290.50
2 b) Manufacturing & Trading of Implants 3,015.10 9,107.90
Total Segment Revenue 27,212.60 85,398.40
Less: Inter segment revenue
Revenue from operations 27,212.60 85,398.40
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
1 a) Healthcare Services 2,004.40 7,820.60
2 b) Manufacturing & Trading of Implants (1,081.40) (2,724.90)
Total Profit before tax 923.00 5,095.70
i. Finance cost 0.00 0.00
ii. Other Unallocable Expenditure net off Unallocable income 0.00 0.00
Profit before tax 923.00 5,095.70
3 (Segment Asset - Segment Liabilities)
Segment Asset
1 a) Healthcare Services 1,22,358.50 1,22,358.50
2 b) Manufacturing & Trading of Implants 55,074.80 55,074.80
Total Segment Asset 1,77,433.30 1,77,433.30
Un-allocable Assets 0.00 0.00
Net Segment Asset 1,77,433.30 1,77,433.30
4 Segment Liabilities
Segment Liabilities
1 a) Healthcare Services (41,303.40) (41,303.40)
2 b) Manufacturing & Trading of Implants (35,976.10) (35,976.10)
Total Segment Liabilities (77,279.50) (77,279.50)
Un-allocable Liabilities 0.00 0.00
Net Segment Liabilities (77,279.50) (77,279.50)
Disclosure of notes on segments



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-10-2025 01-04-2025
B Date of end of reporting period 31-12-2025 31-12-2025
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Consolidated Consolidated
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Remeasurement of the defined benefit plans (7.80) (23.50)
Total Amount of items that will not be reclassified to profit and loss (7.80) (23.50)
2 Income tax relating to items that will not be reclassified to profit or loss (2.70) (8.20)
3 Amount of items that will be reclassified to profit and loss
1 (Gain)/ Loss arising from translating the financial statement of foreign Operation (276.10) (1,016.40)
Total Amount of items that will be reclassified to profit and loss (276.10) (1,016.40)
4 Income tax relating to items that will be reclassified to profit or loss 0.00 0.00
5 Total Other comprehensive income (281.20) (1,031.70)